Viemed Healthcare (VMD) Expected to Announce Quarterly Earnings on Wednesday

Viemed Healthcare (NASDAQ:VMD) is anticipated to post its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect Viemed Healthcare to post earnings of $0.12 per share and revenue of $77.70 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 11:00 AM ET.

Viemed Healthcare Stock Up 2.0%

NASDAQ VMD opened at $8.61 on Thursday. The business has a fifty day moving average price of $7.71 and a 200 day moving average price of $7.14. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.01 and a current ratio of 1.13. The company has a market cap of $327.35 million, a P/E ratio of 26.09 and a beta of 1.27. Viemed Healthcare has a one year low of $5.93 and a one year high of $8.94.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Viemed Healthcare in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Finally, Zacks Research raised shares of Viemed Healthcare to a “hold” rating in a research note on Thursday, January 8th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Institutional Trading of Viemed Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in VMD. Martingale Asset Management L P raised its holdings in shares of Viemed Healthcare by 6.0% in the 4th quarter. Martingale Asset Management L P now owns 42,483 shares of the company’s stock valued at $316,000 after buying an additional 2,399 shares during the period. Invesco Ltd. grew its position in Viemed Healthcare by 17.1% in the 4th quarter. Invesco Ltd. now owns 21,773 shares of the company’s stock valued at $162,000 after acquiring an additional 3,173 shares in the last quarter. Barclays PLC increased its stake in Viemed Healthcare by 2.7% during the fourth quarter. Barclays PLC now owns 131,759 shares of the company’s stock worth $979,000 after purchasing an additional 3,480 shares during the period. Rhumbline Advisers increased its stake in Viemed Healthcare by 9.0% during the second quarter. Rhumbline Advisers now owns 51,456 shares of the company’s stock worth $356,000 after purchasing an additional 4,228 shares during the period. Finally, Gabelli Funds LLC lifted its position in shares of Viemed Healthcare by 4.3% during the second quarter. Gabelli Funds LLC now owns 121,510 shares of the company’s stock worth $840,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 74.24% of the company’s stock.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.